Pharmaceutical manufacturer direct-to-patient (DTP) dispensing is a distribution model in which drug manufacturers bypass traditional pharmacy channels to deliver medications directly to patients. This model is increasingly being used for popular and high-demand medications like GLP-1 receptor agonists where manufacturers can provide streamlined access, better adherence support, and personalized engagement. Proponents argue that DTP enhances convenience, ensures product authenticity, and can reduce delays in starting therapy. However, critics raise concerns about reduced pharmacist oversight, potential gaps in monitoring side effects or interactions, and the implications for patient safety and continuity of care.

PHSL’s August poll suggests that public opinion on the DTP dispensing trend is largely favorable, with 63% of respondents expressing either a highly positive (13%) or mostly positive (50%) view. Full results are provided below.

What is your opinion of the pharmaceutical manufacturer direct-to-patient dispensing trend?

Highly positive: 13%

Mostly positive: 50%

Neutral: 13%

Mostly negative: 25%

Highly negative: 0%